Past, Present, and Future of Pharmacologic Therapy in Obesity

Prim Care. 2016 Mar;43(1):61-7, viii. doi: 10.1016/j.pop.2015.08.011. Epub 2016 Jan 12.

Abstract

Medications for obesity management can be divided into 4 groups: antidepressants (naltrexone/bupropion), stimulants (phentermine, phendimetrazine, diethylpropion, phentermine/topiramate), fat blockers (orlistat), and diabetes medications (liraglutide). Each group has specific therapeutic effects, adverse effects, and costs. Two medications are indicated for long-term use in obesity: lorcaserin and orlistat. Other available medications are for short-term use. High cost makes many of these medications inaccessible for underserved and poor patients. Because of misuse potential, many obesity medications are also classified as controlled substances. There are no medications currently approved for use in pregnant or lactating women.

Keywords: Antidepressants; Fat blockers; Obesity; Pharmacology treatment; Stimulants.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents / therapeutic use*
  • Antidepressive Agents / therapeutic use*
  • Central Nervous System Stimulants / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Obesity / drug therapy*
  • Weight Loss

Substances

  • Anti-Obesity Agents
  • Antidepressive Agents
  • Central Nervous System Stimulants
  • Hypoglycemic Agents